Summary of AngioDynamics 2026 Conference Call Company Overview - **Company**: AngioDynamics (NasdaqGS: ANGO) - **Industry**: Medical Technology - **CEO**: Jim Clemmer - **Conference Date**: March 09, 2026 Key Points Business Evolution and Strategy - AngioDynamics has transformed from a traditional medical device company to a technology-focused entity over the past five years, targeting larger and faster-growing markets where patient outcomes are measurable [8][9] - The company has divested from slower, commodity-based markets and invested in three key areas: cardiovascular platforms and interventional oncology [9] - Simplification of the supply chain has been implemented to reduce unnecessary costs and ensure a clear pathway for future growth [9][10] Financial Performance - The company operates on a unique fiscal year starting June 1, with the most recent quarter ending February 28, 2026 [13] - The Med Device segment, while historically less profitable, has generated cash to support the transformation, while the Med Tech segment has shown nearly 20% growth in the first six months of the fiscal year [14][15] - Gross margins and overall profits have exceeded expectations, leading to an upward revision of guidance after the second quarter [15] Med Tech Segment Insights - The Med Tech segment includes two cardiovascular areas: arterial disease and venous disease, along with interventional oncology using the NanoKnife technology [19] - The Auryon system, launched over five years ago, has generated over $60 million in revenue this year, showcasing strong growth against established competitors [22] - The company has achieved 18 consecutive quarters of double-digit growth, with over 40% of revenue now coming from hospitals [24] Competitive Landscape - The mechanical thrombectomy market is currently 15%-20% penetrated, with AngioDynamics competing against Inari and Penumbra [40] - The AngioVac product is positioned as a high-end catheter-based device, while the newly developed AlphaVac aims to capture the pulmonary embolism (PE) market [42][44] - AlphaVac is expected to surpass AngioVac in sales as it targets a larger market opportunity estimated at $3 billion in the U.S. [49] Product Development and Future Growth - The NanoKnife technology is positioned as a focal therapy option for prostate cancer, targeting the intermediate-risk patient segment [78] - The company is exploring opportunities in benign prostatic hyperplasia (BPH) and aims to expand its product offerings in this area [95] - Ongoing R&D initiatives include potential new devices for deep vein thrombosis (DVT) treatment, leveraging existing technologies [97] Market Challenges and Opportunities - The company faces challenges in securing consistent payment structures for its products, particularly for NanoKnife, which requires ongoing education and awareness efforts [90] - The competitive landscape is evolving, with AngioDynamics focusing on gaining market share from established players while also developing new customer bases [73] Investor Communication - The CEO expressed frustration over the stock's performance relative to the company's achievements, emphasizing the commitment to transparency and delivering on promises made to investors [102] Additional Insights - The company is actively expanding its sales force to support growth in the PE market, with plans to increase from 60 to potentially 100 sales representatives [61] - The CEO highlighted the importance of clinical data and physician confidence in driving product adoption and market penetration [70] This summary encapsulates the key insights and strategic direction of AngioDynamics as discussed in the conference call, providing a comprehensive overview of the company's current status and future outlook.

Core Viewpoint - AngioDynamics, Inc. is a leading medical technology company focused on enhancing blood flow in the vascular system, expanding cancer treatment options, and improving patient quality of life [1] Company Presentation - Jim Clemmer, President and CEO of AngioDynamics, will present at the Leerink Partners Global Healthcare Conference on March 9, 2026, starting at 1:40 p.m. (ET) [1]

Core Insights - AngioDynamics (ANGO) has received expanded indications in Europe for its NanoKnife System, enhancing its clinical utility in soft tissue tumor ablation, specifically for tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer cases [1][8]. Group 1: Expanded Indications and Clinical Utility - The broadened indications allow greater physician access to the NanoKnife System's irreversible electroporation (IRE) technology, which is particularly useful for treating tumors that are difficult to remove or located near vital anatomical structures [2][9]. - The management of ANGO noted increasing clinical adoption of the NanoKnife for prostate indications and aims for further global expansion, highlighting the broader applicability of its IRE technology [3][6]. Group 2: Clinical Evidence and Registry Launch - To support clinical adoption and generate longitudinal evidence, ANGO plans to launch the LIVER-IRE Global Registry in collaboration with the University of Manchester, which will assess real-world outcomes for patients treated with IRE for liver tumors [4][10]. - Clinical evidence for the NanoKnife System's IRE platform is growing, with data from trials indicating procedural success and promising outcomes in various malignancies, reinforcing the technology's safety and value [10][11]. Group 3: Market Position and Growth Potential - ANGO is positioned for significant growth following the European expansion, as broader approvals across multiple tumor types significantly increase its addressable market [6][12]. - Europe accounts for approximately 28% of global IRE procedure volumes, indicating its importance in the overall market and supporting the NanoKnife's multi-organ growth strategy [8][11]. Group 4: Industry Prospects - The tumor ablation market is projected to reach $2.47 billion by 2026, with a CAGR of 13.1% through 2035, driven by rising demand for minimally invasive therapies and advanced therapeutic options [13].

Core Viewpoint - AngioDynamics (ANGO) shares have shown a slight increase of 0.1% over the past four weeks, closing at $10.06, with analysts suggesting a potential upside of 92.2% based on a mean price target of $19.33 [1] Price Targets and Analyst Consensus - The average price target for ANGO ranges from a low of $16.00 to a high of $24.00, with a standard deviation of $4.16, indicating a potential increase of 59.1% to 138.6% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a positive indicator for investors [2][9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ANGO's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.6% over the past month, with no negative revisions, indicating positive sentiment [12] Zacks Rank and Investment Potential - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]

Core Viewpoint - AngioDynamics reported a breakeven adjusted earnings per share for Q2 fiscal 2026, showing improvement from a loss in the previous year, but the stock has underperformed the S&P 500 recently, raising questions about its future performance leading up to the next earnings release [2][1]. Financial Performance - The company achieved pro-forma revenues of $79.4 million in Q2, an 8.8% increase year over year, surpassing the Zacks Consensus Estimate by 4.5% [4]. - U.S. net revenues were $67.6 million, reflecting a 7.8% year-over-year increase, exceeding the estimate of $62.3 million [5]. - Pro-forma international revenues reached $11.8 million, up 8.8% from the previous year, also surpassing projections [5]. Segment Analysis - The Med Tech segment reported pro-forma net sales of $35.7 million, a 13% increase year over year, exceeding the estimate of $32.7 million [6]. - Key drivers included Auryon sales of $16.3 million (up 18.6% year over year) and Mechanical Thrombectomy revenues of $11 million (up 3.9% year over year) [7]. - Pro-forma Med Device revenues totaled $43.8 million, a 5.6% increase from the prior year, also above projections [8]. Margin and Expenses - Pro-forma gross profit increased by 14% to $44.8 million, with gross margin expanding by 170 basis points to 56.4%, surpassing the projected margin of 54.2% [9]. - Sales and marketing expenses rose 4.4% to $26.7 million, while R&D expenses increased by 20.7% to $7.8 million [10]. Cash Position - At the end of Q2 fiscal 2026, AngioDynamics had cash and cash equivalents of $41.6 million, up from $38.8 million at the end of Q1, with no debt on the balance sheet [11]. Guidance and Outlook - The company updated its fiscal 2026 guidance, expecting net sales between $312 million and $314 million, an increase from previous guidance [12]. - Med Tech revenue growth is projected at 14-16%, while Med Device growth is expected to be flat to 1% [13]. - The adjusted loss per share is anticipated to be between 33 cents and 23 cents, with the consensus estimate at a loss of 28 cents [14]. - Estimates have trended downward recently, with a significant revision of -31.25% [15].

Core Viewpoint - AngioDynamics (ANGO) has shown a downtrend recently, losing 6.1% over the past week, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom in the stock price, suggesting that selling pressure may be exhausting [2][5]. - This pattern forms when there is a small candle body with a long lower wick, indicating that despite a downtrend, buyers are starting to emerge [4][5]. - Hammer candles can appear on various timeframes and are used by both short-term and long-term investors [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for ANGO, with a 3.6% increase in the consensus EPS estimate over the last 30 days, indicating analysts expect better earnings [7][8]. - ANGO holds a Zacks Rank of 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9][10]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are improving, further supporting the potential for a turnaround [10].

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong second-quarter fiscal 2026 performance and ongoing studies [1][2] Financial Performance - AngioDynamics reported a revenue increase of 8.8% year over year to $79.4 million in fiscal Q2 2026, with the NanoKnife revenue rising 22.2% due to record prostate cancer procedure volumes [7][10] - The Auryon franchise generated $16.3 million in revenue, reflecting an 18.6% year-over-year growth, marking 18 consecutive quarters of double-digit growth [5][10] - The company has a market capitalization of $422.1 million and projects a 51.9% growth over the next year [2] Growth Drivers - The NanoKnife franchise is a key growth driver, with probe sales increasing 14.4% year over year, attributed to rising adoption in prostate cancer procedures [3][4] - Management noted steady adoption of NanoKnife, supported by procedural growth and increasing clinical utilization, particularly in the prostate cancer market [4] - The mechanical thrombectomy portfolio saw a revenue increase of 3.9% year over year to $11 million, with AlphaVac achieving over 40% growth [9] Market Position and Trends - AngioDynamics has gained 9.8% in share price over the last six months, outperforming the industry growth of 5.2% and the S&P 500's increase of 11.9% [1] - The company has been experiencing a positive estimate revision trend, with the Zacks Consensus Estimate for loss narrowing to 27 cents per share for fiscal 2026 [13] Challenges - Management acknowledged ongoing tariff-related costs of $4–$6 million for the fiscal year, which may pose a structural margin headwind [11][12]

Core Viewpoint - AngioDynamics has undergone a significant transformation over the past five years, shifting from a focus on interventional radiology to a more scientifically-driven portfolio aimed at larger, addressable markets [3]. Company Transformation - The company started as an interventional radiology-based entity in upstate New York, building a strong legacy within that community [3]. - Over the last five years, AngioDynamics has focused on refreshing its portfolio, which included three divestitures to exit certain markets [4].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - AngioDynamics is experiencing significant growth in its MedTech portfolio, particularly with the Auryon platform, which has generated over $60 million in revenue this year, up from zero at launch in September 2020 [1][4] - The company is transitioning from a legacy interventional radiology focus to a more science-driven MedTech portfolio, targeting larger and faster-growing markets [2][3] - CEO Jim Clemmer plans to retire later this year but will remain involved as a major shareholder and advisor during the leadership transition [4][17] Product and Market Developments - Auryon, a laser-based atherectomy platform, has seen nearly 20% growth year-to-date, with increased traction in hospitals and higher average selling prices [5] - The AlphaVac system, targeting pulmonary embolism, is positioned as a differentiated product in the VTE market, which is still early in its penetration curve, with only about 15% market penetration [6][7] - NanoKnife, used for treating intermediate-risk prostate cancer, has received an on-label indication and is expected to expand into benign prostatic hyperplasia (BPH) [8][9][16] Financial Performance and Projections - AngioDynamics is debt-free with positive adjusted EBITDA and expects to be cash-flow positive by fiscal 2026, with MedTech products projected to exceed 50% of revenue by fiscal 2027 [4][11][14] - The company's MedTech products have achieved a 25% compound annual growth rate over the past five years, with continued growth anticipated [10][11] - Management plans to optimize the portfolio further as MedTech becomes a larger share of the business, with no substantial M&A expected in the near term [13][14] Leadership Transition - The company will conduct a deliberate search for a new CEO, considering both internal and external candidates, with no rush to finalize the appointment [17][18] - Clemmer's retirement is based on personal circumstances, and he feels confident in the company's recent execution and results [17][18]